- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | BIODLINK-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | 7 | HKEx | ||
| 27.10. | BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia | 177 | PR Newswire | Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1].
This inaugural... ► Artikel lesen | |
| 16.10. | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF ... | 1 | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 13.10. | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 13.10. | BIODLINK-B (01875): CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF BOARD COMMITTEE | 1 | HKEx | ||
| 26.09. | BIODLINK-B (01875): INTERIM REPORT 2025 | - | HKEx | ||
| 14.08. | BIODLINK-B (01875): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 14.08. | BIODLINK-B (01875): LETTER TO REGISTERED SHAREHOLDERS - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 14.08. | BioDlink's bevacizumab receives marketing approval in Colombia, Pakistan | 1 | Pharmaceutical Business Review | ||
| 12.08. | BIODLINK-B (01875): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 31.07. | BIODLINK-B (01875): DATE OF BOARD MEETING | - | HKEx | ||
| 25.07. | TOT BIOPHARM-B (01875): AMENDED AND RESTATED ARTICLES OF ASSOCIATION | - | HKEx | ||
| 25.07. | TOT BIOPHARM-B (01875): CHANGE OF COMPANY ENGLISH NAME, AMENDMENTS TO THE ARTICLES OF ASSOCIATION, CHANGE OF STOCK SHORT NAME, CHANGE OF COMPANY WEBSITE ... | - | HKEx | ||
| 30.06. | TOT BIOPHARM-B (01875): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | - | HKEx | ||
| 20.06. | TOT BIOPHARM-B (01875): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 20 JUNE 2025 | - | HKEx | ||
| 21.03. | EQS Newswire: TOT BIOPHARM Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M | 450 | EQS Group (EN) | EQS Newswire / 21/03/2025 / 22:00 UTC+8
Guru Club, March 12 - TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 186,15 | +4,02 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 41,260 | +10,77 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| NUVALENT | 106,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,960 | +1,80 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| BEAM THERAPEUTICS | 26,740 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,200 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 39,920 | -1,20 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| JANUX THERAPEUTICS | 17,110 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 42,610 | 0,00 % | CG Oncology appoints Christina Rossi to board of directors | ||
| SUMMIT THERAPEUTICS | 18,370 | 0,00 % | Don't Buy Summit Therapeutics Until This Big Thing Happen | ||
| NURIX THERAPEUTICS | 16,830 | +2,94 % | Nurix to host webcast on bexobrutideg clinical data next week | ||
| AVIDITY BIOSCIENCES | 71,58 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| DISC MEDICINE | 92,38 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| IMMUNOME | 19,370 | 0,00 % | Truist Securities initiates coverage on Immunome stock with Buy rating | ||
| RECURSION PHARMACEUTICALS | 4,665 | 0,00 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI |
Das Unternehmen BIODLINK INTERNATIONAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.